Wednesday, April 06, 2022 11:39:01 AM
rickster... you raise good questions. I'm becoming concerned with their cash burn, their cash position (I think is < than 10M), and their 320M O/S and float. I'm 98% sure that Michael Frank executed a R/S in a previous position somewhere (I can't locate that link now). Have you done any DD on the risk of an R/S with RVVTF? They have no real revenues, and the bills are piling up fast with the FDA trial.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
